<?xml version="1.0" encoding="UTF-8"?>
<p id="p0265">LAV developers should consider reassortment in experimental studies of vaccine candidates and to provide a risk-based analysis of vaccine safety. WHO should consider adding language encouraging vaccine developers to consider reassortment in a vaccine-specific risk-based analysis, considering the factors listed in the Brighton Collaboration document 
 <xref rid="b0165" ref-type="bibr">[33]</xref> and the risks and benefits of vaccine use in both epizootic/epidemic and endemic settings.
</p>
